Q4e numbers to mark a strong end to '23 with no major surprises '24e: We expect 26% ARR growth and b...
Mendus has reported FY23 results, summarising an active period.
Challenging market in Q4 EBIT estimates cut by 5-10% for 2024-25e 2024e EV/EBIT of 4x with 4-5% divi...
On February 14th, Eevia Health published the company’s quarterly report for Q4-23.
Q4 sales SEK 27.9m, up 29% y-o-y, adj. EBIT SEK -6.
1% organic sales growth y-o-y Profitability still at a good level Lower utilisation rather than drop...
Endomines H2 figures were negatively impacted by the production method change in Pampalo and prepara...
Rapporten för det fjärde kvartalet kom in något bättre än Analysguidens förväntningar.
Costs in DE remain high, one month with Rudd in numbers We leave estimates mostly unchanged, FX the ...
Active Biotech flaggar för tre nya studier under 2024 samtidigt som den pågående studien inom multip...
Q4 – fortsatt stabilitet i försäljningen Corlines Q4-rapport var i linje med våra förväntningar.
Förtroendegivande avslutning på 2023 Senzagen presterade starkt i Q4(23) med en nettoomsättning som ...
DevPorts försäljning minskade något i Q4 trots prisökningar.
Fastighetsservicebolaget rapporterade över Analysguidens förväntningar, både vad gäller nettoomsättn...
Redeye is encouraged to see that Railcare has raised its financial targets in conjunction with annou...
Redeye saw a Q4 report that was again weaker than expected.
Nettoomsättningen kom in högre än väntat. Försäljningen som landade på SEK69m var mer i linje med vå...
Redeye provides its initial take on Mentice’s Q4 2023 report, which came in broadly below our estima...
Q4 sales lower than expected, mainly on delayed product sales Strong CF driven by WC improvements Sh...
Sales -6% and adj. EBIT SEK -1.5m vs. ABGSCe Growth driven by GC&MP and FW, while NW&FT underperform...